
Waters (WAT) Stock
Leading maker of laboratory testing equipment for drug companies. Here's the price, business snapshot, and what's worth knowing about Waters in November 2026.
Waters Corporation (WAT) designs and manufactures laboratory analytical instruments — notably high-performance liquid chromatography and mass spectrometry systems — used to separate, identify and quantify chemical compounds. Its products, consumables and services serve pharmaceutical, biotech, chemical, food-safety and environmental laboratories worldwide. Revenue typically comprises capital equipment sales and recurring aftermarket consumables and service contracts, which can provide resilient cash flow but remain sensitive to capital spending cycles. Waters benefits from a strong installed base, long product lifecycles and regulatory-driven demand in drug development and quality control. Key considerations for investors include exposure to global pharmaceutical investment, competition from other instrument makers, currency and supply-chain risks, and the ongoing need for R&D. Market cap: $20.79B. This is general information for education, not personalised advice; values can rise or fall and past performance is not a guide.
Why It’s Moving

Waters Secures FDA Clearance for Blood Cancer Tests and Expands Proteomics Capabilities
- The company received FDA 510(k) clearance for two flow cytometry tests targeting leukemia and lymphoma, offering 96.3% sensitivity and reducing manual workflow steps by 95%.
- Waters acquired MOBILion Systems to expand its proteomics footprint, enhancing mass spectrometry capabilities and supporting AI-driven research prospects.
- Recent stock performance contributed positively to mid-cap fund returns, reflecting investor confidence in Waters' diagnostic expansion strategy.

Waters Secures FDA Clearance for Blood Cancer Tests and Expands Proteomics Capabilities
- The company received FDA 510(k) clearance for two flow cytometry tests targeting leukemia and lymphoma, offering 96.3% sensitivity and reducing manual workflow steps by 95%.
- Waters acquired MOBILion Systems to expand its proteomics footprint, enhancing mass spectrometry capabilities and supporting AI-driven research prospects.
- Recent stock performance contributed positively to mid-cap fund returns, reflecting investor confidence in Waters' diagnostic expansion strategy.
Six-Month Growth Performance
When is the next earnings date for WATERS CORP (WAT)?
Waters Corporation has not yet announced a confirmed date for its next earnings release. Based on the historical reporting pattern, where the company typically reports approximately three months after the previous quarter's close, the upcoming report is expected in February 2027. This scheduled update will cover financial results for the fourth quarter of fiscal year 2026. Investors should monitor official corporate communications for the precise announcement of this future reporting date.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Waters Corp stock as it has potential to increase in value.
Financial Health
Waters Corp shows strong revenue, profits, and cash flow, reflecting solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Aftermarket Revenue Strength
Consumables and service contracts create steady recurring income that can stabilise revenue, though instrument orders remain cyclical and can vary.
Pharma & Regulation Demand
Demand from drug development and regulatory testing supports long-term need for high-end instruments, but exposure to regulatory cycles and geographic shifts adds variability.
Innovation & Competition
Continued R&D keeps the product line competitive in high-precision analytics, yet heavy R&D spend and rival technologies present execution risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.